Copyright ©The Author(s) 2018.
World J Gastroenterol. Jul 7, 2018; 24(25): 2764-2775
Published online Jul 7, 2018. doi: 10.3748/wjg.v24.i25.2764
Table 1 Summary of randomized, placebo-controlled, double-masked trials included
StudyFollow-up duration (wk)Anti-TNFα treatment
Hanauer et al[44], 200640225074
Colombel et al[47], 20075225170261
Sandborn et al[35], 2007a52037018
Sandborn et al[34], 2007b401590166
Rutgeerts et al[37], 201248064065
Watanabe et al[28], 201252025025
Watanabe et al[28], 20124067023
Certolizumab pegol
Winter et al[27], 200412066024
Schreiber et al[30], 2005200145073
Sandborn et al[36], 2007c2603310329
Schreiber et al[31], 20072012160212
Sandborn et al[33], 2011602230215
UCB Pharma[42], 201436087087
Targan et al[29], 199712083025
D’Haens et al[46], 1999402208
Present et al[41], 199918063031
Rutgeerts et al[38], 199936037036
Hanauer et al[45], 20024413850188
Sands et al[32], 20044001390143
Lémann et al[43], 200652057058
Colombel et al[48], 20103011690170
Regueiro et al[40], 201152011013
Regueiro et al[39], 201610411470150
Table 2 Risk of Mycobacterium tuberculosis infection associated with the use of tumor necrosis factor-alpha inhibitors in patients with Crohn’s disease
nRisk estimate95%CIP value
Risk difference odds ratio230.028(0.0011, 0.055)0.042
Including Double-Zero Studies234.85(1.02, 22.99)0.047
Excluding Double-Zero Studies55.85(1.13, 30.38)0.036
Table 3 Estimated absolute incidence of Mycobacterium tuberculosis infection in patients with Crohn’s disease treated with tumor necrosis factor-alpha inhibitors and the number of patients with Crohn’s disease who need to be treated with tumor necrosis factor-alpha inhibitors to expect one Mycobacterium tuberculosis case
Incidence of TB with TNFα treatment (cases/person-years)1Number of patients treated to see one TB Case in one year
Based on risk difference177/100000565
Based on relative odds estimated with background correction97/1000001031
Based on relative odds estimated without background correction117/100000855